• Company
• Hemophilia A treatment market sales were 66 billion won
• by Kim, Jin-Gu Mar 8, 2023 05:53am

• Company
• 'Vabysmo’s 4mth dosing interval may reduce patient burden'
• by Jung, Sae-Im Mar 8, 2023 05:53am

• Company
• Self-administered Kynteles lands at general hospitals
• by Eo, Yun-Ho Mar 8, 2023 05:52am

• Policy
• PVA, the higher the bill, the greater the discount rate
• by Lee, Tak-Sun Mar 8, 2023 05:52am

• Company
• Celltrion Healthcare published clinical result of Remsima SC
• by Hwang, Jin-joon Mar 8, 2023 05:51am

• Policy
• Free vaccination of Rotarix·RotaTeq is available
• by Lee, Jeong-Hwan Mar 7, 2023 05:39am

• Policy
• ‘Improve rare disease designations standards for equity'
• by Lee, Jeong-Hwan Mar 7, 2023 05:38am

• Company
• Exkivity applies for reimbursement
• by Eo, Yun-Ho Mar 7, 2023 05:38am

• Policy
• ‘RSA may be applied to non-rare innovative new drugs'
• by Lee, Jeong-Hwan Mar 7, 2023 05:38am

• Company
• Boryung officially launches Zepzelca
• by Kim, Jin-Gu Mar 6, 2023 05:56am